Literature DB >> 3669771

Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia.

E Estey1, W Plunkett, D Dixon, M Keating, K McCredie, E J Freireich.   

Abstract

The cytotoxic effect of cytosine arabinoside (ara-C) is presumably mediated by cytosine arabinoside 5'-triphosphate (ara-CTP). We tested for a correlation between intracellular ara-CTP pharmacokinetics and clinical response among 51 patients who received high dose ara-C (3 g/m2 at 12-hr intervals) as therapy for refractory acute leukemia. After accounting for pretreatment clinical variables that correlated with response, measurement of ara-CTP pharmacokinetics added significant prognostic information. This provides a rationale for manipulation of schedules of high dose ara-C administration in those patients whose pharmacokinetic characteristics are inconsistent with response to an every 12-hr schedule.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3669771

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


  19 in total

Review 1.  The use of genomic information to optimize cancer chemotherapy.

Authors:  Federico Innocenti; Nancy J Cox; M Eileen Dolan
Journal:  Semin Oncol       Date:  2011-04       Impact factor: 4.929

Review 2.  Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.

Authors:  W Hiddemann
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

3.  Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.

Authors:  Elias Jabbour; Guillermo Garcia-Manero; Jorge Cortes; Farhad Ravandi; William Plunkett; Varsha Gandhi; Stefan Faderl; Susan O'Brien; Gautam Borthakur; Tapan Kadia; Jan Burger; Marina Konopleva; Mark Brandt; Xuelin Huang; Hagop Kantarjian
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-04-24

Review 4.  Pharmacogenomic discovery using cell-based models.

Authors:  Marleen Welsh; Lara Mangravite; Marisa Wong Medina; Kelan Tantisira; Wei Zhang; R Stephanie Huang; Howard McLeod; M Eileen Dolan
Journal:  Pharmacol Rev       Date:  2009-12       Impact factor: 25.468

5.  Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.

Authors:  Nikolas Herold; Sean G Rudd; Linda Ljungblad; Kumar Sanjiv; Ida Hed Myrberg; Cynthia B J Paulin; Yaser Heshmati; Anna Hagenkort; Juliane Kutzner; Brent D G Page; José M Calderón-Montaño; Olga Loseva; Ann-Sofie Jemth; Lorenzo Bulli; Hanna Axelsson; Bianca Tesi; Nicholas C K Valerie; Andreas Höglund; Julia Bladh; Elisée Wiita; Mikael Sundin; Michael Uhlin; Georgios Rassidakis; Mats Heyman; Katja Pokrovskaja Tamm; Ulrika Warpman-Berglund; Julian Walfridsson; Sören Lehmann; Dan Grandér; Thomas Lundbäck; Per Kogner; Jan-Inge Henter; Thomas Helleday; Torsten Schaller
Journal:  Nat Med       Date:  2017-01-09       Impact factor: 53.440

6.  Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.

Authors:  V I Avramis; R A Mecum; J Nyce; D A Steele; J S Holcenberg
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  Biochemical interactions between methotrexate and 1-beta-D-arabinofuranosylcytosine in hematopoietic cells of children: a Pediatric Oncology Group study.

Authors:  E M Newman; D G Villacorte; A M Testi; R A Krance; M B Harris; Y Ravindranath; D Pinkel
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 8.  Therapeutic drug monitoring of antimetabolic cytotoxic drugs.

Authors:  L Lennard
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

9.  Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.

Authors:  L V Ramilo-Torno; V I Avramis
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.

Authors:  Olatoyosi M Odenike; Richard A Larson; Devika Gajria; M Eileen Dolan; Shannon M Delaney; Theodore G Karrison; Mark J Ratain; Wendy Stock
Journal:  Invest New Drugs       Date:  2008-01-24       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.